TGM2 and scleroderma: The availability of a human specific monoclonal antibody for TGM228 provides extra impetus toward the potential use of TGM2 blockade in scleroderma and would significantly add to the increasing number of antifibrotic therapies available or currently under investigation for this scleroderma.